Navigation Links
First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
Date:5/4/2009

LONDON, May 4 /PRNewswire/ -- A synthetic peptide H1N1 vaccine is available now for testing worldwide, from Replikins Ltd. The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way (http://www.replikins.com). A unique advantage of the Replikins vaccine is its rapid availability; the WHO, CDC and others have stated that conventionally developed H1N1 vaccines will not be ready for many months. This key advantage is based on the company's ability to swiftly identify, and make molecular vaccines based on, key sub-sequences of the virus genome that are critical to its rapid replication. In contrast with the decades-old production techniques used for most vaccines, the company also takes full advantage of modern peptide synthesis techniques to allow rapid production of its vaccines.

In April 2008, Replikins Ltd. announced the likelihood of H1N1 outbreaks based on the company's patented Replikin Count(TM) genomics technology, which examines specific regions in virus genes that have been linked with past epidemics. The company's chairman, Dr. Samuel Bogoch, found that some of these regions have been conserved for decades. In H1N1 last year the company detected the highest concentrations of these specific regions ever seen, except for those from the 1918 flu pandemic which killed tens of millions of people. To date, no other method has been able to predict whether and what strain of a given organism will threaten a human or animal population.

The same proprietary technology, based on genomic Replikin Count(TM), which permitted one year of advance warning that H5N1 with higher human lethality would strike in 2007, and that H1N1 would strike this year, has been used to manufacture synthetic conserved Replikin vaccines against both these influenza strains, Replikins H5N1 Bird Flu Vaccine(TM) and Replikins H1N1 Swine Flu Vaccine(TM), as well as a Replikins PanFlu Vaccine(TM).

The company is producing the new H1N1 vaccine product after achieving independent test results of the safety and efficacy of its synthetic vaccines against two viruses in two different host populations: the lethal Taura virus in shrimp populations, and the avian flu (H5N1) in chicken populations. The company's closely related Replikins vaccine against H5N1 avian flu, produced in a 7-day period, was recently tested at the University of Georgia and shown to block H5N1 virus entry, replication, and excretion in chickens (paper submitted for publication).

Institutions requesting Replikins' H1N1 vaccine for testing should contact John McKenney at jmckenney @ replikins.com; +1-617-536-0220.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):